Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection

Ta, Chen; Chau, Gar Yang; Lee, Rheun‐Chuan; Chen, Yen Ying; Lei, Hao Jan; Hou, Ming; Chao, Yee; Huang, Yi Hsiang

doi:10.1016/j.jfma.2019.02.012

Cited by 17 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, cirrhosis and HBV infection are more commonly related with cHCC-CCA than iCCA, although with lower rates compared to HCC[ 91 - 94 ]. Most patients are aged between 50 and 60 years, with comparative studies claiming presentation in a younger age than iCCA[ 91 , 95 ], while others have not managed to point out significant age differences[ 92 , 93 ]. Male predominance is well documented (65%-80%)[ 89 , 90 , 95 , 96 ] and tends to be more notable opposed to iCCA patients[ 92 ].…”

Section: The Case Of Combined Hcc and Cholangiocarcinomamentioning

confidence: 99%

“…Imaging features may resemble patterns of HCC, CCA, or both, therefore rendering radiological modalities insufficient to ensure definite diagnosis. Arterial phase hyperenhancement and portal/delayed phase hypoenhancement (washout) are characteristic findings of HCC in CT, MRI, and contrast-enhanced ultrasound; however, they could also be displayed by cHCC-CCA lesions and lead to misdiagnosis[ 93 , 99 ]. Similarly, cHCC-CCA tumors can mimic CCA by displaying gradual enhancement and peripheral irregular rim-like contour.…”

Section: The Case Of Combined Hcc and Cholangiocarcinomamentioning

confidence: 99%

See 1 more Smart Citation

Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?

Fragkou¹,

Sideras²,

Panas³

et al. 2021

WJG

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCCA) is a subgroup of cholangiocarcinoma that accounts for about 10%-20% of the total cases. Infection with hepatitis B virus (HBV) is one of the most important predisposing factors leading to the formation of iCCA. It has been recently estimated based on abundant epidemiological data that the association between HBV infection and iCCA is strong with an odds ratio of about 4.5. The HBV-associated mechanisms that lead to iCCA are under intense investigation. The diagnosis of iCCA in the context of chronic liver disease is challenging and often requires histological confirmation to distinguish from hepatocellular carcinoma. It is currently unclear whether antiviral treatment for HBV can decrease the incidence of iCCA. In terms of management, surgical resection remains the mainstay of treatment. There is a need for effective treatment modalities beyond resection in both first- and second-line treatment. In this review, we summarize the epidemiological evidence that links the two entities, discuss the pathogenesis of HBV-associated iCCA, and present the available data on the diagnosis and management of this cancer.

show abstract

Section: The Case Of Combined Hcc and Cholangiocarcinomamentioning

confidence: 99%

Section: The Case Of Combined Hcc and Cholangiocarcinomamentioning

confidence: 99%

Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?

Fragkou¹,

Sideras²,

Panas³

et al. 2021

WJG

View full text Add to dashboard Cite

show abstract

“…Allen and Lisa into three histological types; A, B, and C as described in CHC should be suspected in patients with a discordant pattern between imaging and tumor markers [2,3]. To meet the diagnostic criteria, the sample must show indisputable evidence of hepatocellular and biliary differentiation.…”

Section: Discussionmentioning

confidence: 99%

“…Combined hepatocellular-cholangiocarcinoma (CHC) is a rare and aggressive primary hepatic malignancy consisting of combined phenotypical characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) [1]. The incidence of CHC is between 1-4.7% of all diagnosed primary liver tumors; however, it has been increasingly identified due to advances in immunohistochemistry (IHC) staining and genetic analysis [1,2,3], with a reported incidence of 0.4-14.2% across a number of studies. Despite being a distinct entity, there are no clear guidelines for managing these tumors, and surgical resection is the preferred treatment, with high curative rates [1,4,5].…”

Section: Introductionmentioning

confidence: 99%

Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer

Ayas¹,

Affas²,

Ayas³

et al. 2021

Cureus

View full text Add to dashboard Cite

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare primary tumor of the liver. Histologically, it comprises components of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) but is associated with a worse prognosis. International guidelines regarding its management are scarce, with surgical management (major hepatectomy) being the treatment of choice. In this report, we present a challenging case of a 73-year-old male with primary CHC who was not a surgical candidate but underwent hepatic artery radioembolization instead.

show abstract

“…Epidemiology cHCC-ICC is likely to comprise between 0.4 and 4.7% of all PLCs, incidence ratio for male:female patients is 1.8-2.1:1 and median age at diagnosis is 62-65 years-old (2,(6)(7)(8)(9)(10)(11)(12). Data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute reveals that patients tend to present with distant, metastatic disease (130/380, 34.2%) rather than localized (98/380, 25.8%) or regional disease (97/380, 25.5%) according to their generic staging system (vida infra) (11, 12).…”

Section: Introductionmentioning

confidence: 99%

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.

show abstract

Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection

Cited by 17 publications

References 31 publications

Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?

Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?

Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Contact Info

Product

Resources

About